Endoscopic removal of slow release oxycodone tablets in a case of voluntary acute poisoning

Sossio Serra, Stefano Geniere Nigra

Emergency Department, Maurizio Bufalini Hospital, Cesena (FC), Italy

Abstract

We describe a case of 83-years-old women admitted to the Emergency Department after voluntary ingestion of tablets of Oxycodone 10 mg slow release for suicide purpose. Out-of-hospital emergency system were activated 45 minutes after voluntary ingestion of referred 28 tablets of Oxycodone 10 mg slow release for suicide purpose. After 2 hours from drug ingestion Esophagogastroduodenoscopy (EGDS) was performed and a number of tablets have been removed. Intoxication symptoms completely resolved and Naloxone infusion has been stopped. The clinical courses of this intoxication suggest that the utility of EGDS to remove tablets should be considered in selected cases of drug poisoning.

Case Report

We describe a case of a 83-years-old woman attended to the Emergency Department after voluntary ingestion of referred 28 tablets of Oxycodone 10 mg slow release for suicide purpose. Out-of-hospital emergency system were activated 45 minutes after ingestion. The patient has a medical history of arterial hypertension, hypercholesterolemia, pacemaker implantation for seno-atrial disease, diffuse arthrosis and osteoporosis with recent rotule fracture leading a partial loss of autonomy. Medical therapy was bisoprolol 2.5 mg, atorvastatine 20 mg, canrenone 25 mg. When emergency medical service arrived, the patient was drowsed, but awake if verbal stimulatd Glasgow Coma Scale (GCS) 14. Bilateral myotic pupils. Blood Pressure was 140/70 mmHg, Heart Rate 90 bpm, Peripheral O2 Saturation 96% in room air with transient bradypnea. After Naloxone 0.4 mg intravenous (IV) administration to reverse respiratory depression, we assisted to retrieval of normal consciousness and breathing. During the transfer to the hospital vomiting occurred and nasogastric tube has been placed. No pills traces have been detected by gastric lavage from nasogastric tube. In-hospital first evaluation documented drowsiness and transient bradypnea. Clinical head-to-toe evaluation showed only myotic pupils. Normal blood pressure and heart rate were reported. Second dose of Naloxone 0.4 mg IV have been administrated followed by a third intramuscular dose with rapid consciousness improvement and interruption of the bradypnea. Considering the GCS 15, time of ingestion (more or less one hour), and the compliance of the patient, gastric lavage with 40 French orogastric tube has been performed. Only few tablets were retrieved. Intravenous continuous Naloxone 0.025 mg/kg/h infusion was started. Considering the high dose of Oxycodone ingested and the slow release pharmacological cinesis, according with the Poisoning Center and endoscopy specialist, we decided to perform EGDS two hours after ingestion. The EGDS reported regular esophagus, cardias incontinence for hiatal hernia, hyperemic gastric mucosa with erosive spots, normal duodenum mucosa. Near the gastric bottom 14 pills were highlighted, another pill was found on duodenal bulb level. Using a small net and in multiple steps approach, all pills were removed (Figure 1 and 2). No bezoar was found. After the procedure the patient appeared with GCS 15 and myosis disappeared. Normal cardiopulmonary findings have been documented. Oral activated charcoal 50 mg was administered followed by 30 mg of magnesium sulphate (which had not been administered previously considering the performance of endoscopic procedure) to prevent the possible post pyloric absorption. After one hour, IV continuous Naloxone infusion was stopped and the patient was admitted to sub-intensive ward for observation because the high risk of delayed or secondary opioid peak. Naloxone administration was not necessary anymore. Only a qualitative drug essay was performed. No substance abused were demonstrated other than opioids. Clinical course was regular and without complications, on day 3 the patient was discharged after psychiatric evaluation, prescribing antidepressant therapy.

Discussion

Gastric decontamination is the main approach to the patient with incongruous pills oral intake. Official guidelines are missing
but we have a number of position papers and statements made by the most important international scientific societies, such as the American Academy of Clinical Toxicology (AACT) and the European Association of Poison Centers and Clinical Toxologist (EAPCCT) providing the practical approach to this situation. Gastric decontamination techniques (gastric lavage, activated charcoal and emetics) have specific indications and contraindications, and AACT/EAPCCT statements do not recommend their routine application. Clinical studies showed that there is high variability in relation of the amount of substances that may be removed by gastric decontamination, depending on several factors including the characteristics of the substance, its formulation (for example compounds of prolonged release), the time of ingestion and the dose taken. Pharmaceutical agent factors, both intrinsic (tablet size, persistence, adhesiveness, viscosity) and extrinsic (anti-cholinergic or opiate effects, ability to cause pylorospasm or GI tract atony) should also be considered. Agglomerates of tablets (bezoar) can represent an obstacle to effectiveness of gastric decontamination. As recently reported by Hoegberg et al., when some components are present in slow release formulation drugs (eg. hypromellose or alginate or acrylate), clinicians should be alert for risk of pharmacobezoar formation. Oxicodone 10mg SR contain hypromellose; this aspect could be the main reason why this drug forms bezoars.

Moreover, tablets can strictly adhere to the gastric wall mucosa leading to ineffectiveness of traditional decontamination strategies. In these specific cases, direct postero-anterior abdomen radiography may help to identify macro-aggregates of tablets. Because of that sometimes we need to consider the possibility to perform EGDS to remove tablets. There are no specific or standardized indications to perform EGDS in intoxicated patient and how to treat pharmacobezoars. Examples of forced elimination of pharmacobezoars have been reported by several different procedures either by breakage using carbonated beverage as ingestion and/or intrabezoar injection or removal by endoscopic capture with or without prior fragmentation, rectal removal, or surgery. Saeki et al. described a case of 50 pills slow-release Theophylline tablets ingestion. Pills aggregation was reported performing abdominal radiography but gastric lavage was useless to remove the bezoar. The EGDS performed 3 hours after ingestion removed 31 tablets. Djogovic et al. described a voluntary Venlafaxine ingestion that lead to bezoar removal by EGDS. Hojer and Personne reported other 2 cases of pills removal by EGDS, in one case the procedure has been performed after 5 hour of Chlorimipramine ingestion. Schwerk et al. reported a suicidal attempt by ingestion of Ethylefrine removed by EGDS after a failed attempt with gastric lavage. All author above agree about EGDS indication only after a failed attempt of the classical gastric decontamination approach. The clinical case we reported follows the experience of the authors above, leading the EGDS as a rescue therapy when classical gastric decontamination fails though intoxication by drugs with long release formulations or dangerous for life. Every patient with massive pills ingestion needs a specific evaluation and may request a multidisciplinary approach.

**Conclusions**

Despite spontaneous emesis and gastric lavage performed in Emergency Department we did not detect any drug traces, and the EGDS made two hours after ingestion removed several tablets, contributing decisively to resolve Oxicodone overdose. There was a rapid resolution of intoxication symptoms after drug removal and the administration of Naloxone has no longer been necessary. In the case of massive acute overdoses, worsening clinical condition or rising serum drug concentrations after aggressive gastric decontamination should raise the possibility of a pharmacobezoar.

**References**

3. Hoegberg LCG, Refsgaard F, Pedersen SH et al. Potential pharmacobezoar formation of large size extended-release

---

**Figure 1. Oxicodone tablets seen in gastroscopy.**

**Figure 2. Oxycodeone tablets removed by gastroscopy.**


